top of page


Right of Assembly is my personal blog. All opinions are my own. You can read more about me here.


I am a ChromaDex shareholder, and an affiliate marketer. As a result, I will sometimes mention or recommend products that I endorse. I may earn a small commission from qualifying purchases if you were referred directly from this site and completed a purchase. [Thank you!] You can read more about our advertising, privacy, and data collection policies here. 


This site uses cookies. Cookies are not required for site functionality. You can read more about how to opt-out of cookies here.

  • Writer's pictureShelly Albaum

CDXC Short Interest Chart - March '18

Short interest was up by about 5% or 200,000 shares between March 15 and March 29 ( from 3.9M to 4.2M), while price fell about 10% from $4.72 to $4.20.

Although it is a yet another new high for the shorts, the price drop seems disproportionate, suggesting that something else was afoot, too -- perhaps a big seller reduced their holdings, or Geoff the Troll finally took his money and went home.

It was TWO months ago that the FDA sent its interim response promising that ChromaDex's petition was under "active evaluation." It's been FIVE months since briefing was completed on ChromaDex's motion to dismiss Elysium's SDNY complaint ABOUT the FDA petition.

I'm pretty sure that ChromaDex has a Noerr-Pennington right to ask the FDA to enforce against all competitors the rules that ChromaDex is complying with, regardless of whether the FDA ever acts on the petition, so Judge Caproni ought (in my view) to not wait indefinitely to throw out Elysium's complaint. However, it will obviously be an exceedingly-short-and-easy opinion to write if the FDA does in fact act on the petition in any way, and SDNY usually has bigger fish to fry, so I can't actually blame Her Honor for letting this one stew.

121 views0 comments

Recent Posts

See All
bottom of page